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Analgesics promote welfare and sustain
tumour growth in orthotopic 4T1 and B16
mouse cancer models
Jennifer Lofgren1, Amy L Miller2, Claudia Chui Shan Lee3,
Carla Bradshaw3, Paul Flecknell3 and Johnny Roughan3
Abstract
Murine orthotopic cancer models often require surgery, potentially causing pain or distress. However, anal-
gesics are often withheld because they may alter tumour development. Two orthotopically implanted cancers
were investigated in mice pre-treated with meloxicam (10 mg/kg), buprenorphine (0.2 mg/kg) or saline
(1 ml/kg). Tumours were imaged and welfare was assessed using body weight, behaviour and nociceptive
responses. In study 1, BALB/c mice were inoculated with 4T1 mammary carcinoma or saline during surgery or
anaesthesia. As pre-treatment with a single buprenorphine dose appeared beneficial to cancer growth con-
sistency, a second cohort of mice additionally received saline or buprenorphine at 12 and 24 h. Surgery
resulted in increased mammary tumour growth and lung metastases. These unwanted effects were lessened
by buprenorphine pre-treatment, especially when given repeatedly. Mammary tumour-bearing mice became
less active and nociceptive thresholds declined over time, indicating some discomfort as tumours grew. In
study 2, C57BL/6 mice received B16 melanoma. This non-surgical model was used to determine whether
meloxicam or buprenorphine affected cancer seeding of the lungs. While meloxicam reduced B16 lung
seeding, buprenorphine did not. Mechanical thresholds decreased as cancer developed in mice bearing
melanoma, but the magnitude of this was insufficient to conclude that there were any significant welfare
concerns. This study highlights the scientific value in utilising non-surgical models, where possible. When
surgery must be performed at the time of tumour inoculation, the effects of this should be controlled with
appropriate analgesics to enhance the value and possibly translation of the research.
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Large numbers of mice are involved in cancer research.
Many receive orthotopic tumour inoculation, whereby
tumours grow in the tissue of origin. This approach is
supposed to maximise the translational relevance of
results,1,2 whereas with heterotopic tumour inoculation
tumours grow in an unrelated tissue, for example sub-
cutaneously. The tumour cells implanted may be from
different strains of mice or even different species. They
can be grown in immunocompromised mice, or as in
this case, they can be syngeneic derived tumour cell
lines. Although tumour inoculation can be a minimally
invasive procedure, some procedures such as intra-
ocular injection may not be, and some models require
surgery, for example laparotomy to implant hepatocel-
lular carcinoma. Although this could be painful,
analgesics are often withheld due to concerns about
their potentially confounding effects on tumour devel-
opment. A search for the terms ‘mouse AND tumour
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AND surgery’ on https://www.ncbi.nlm.nih.gov
resulted in 49,266 articles. When combined with the
terms ‘analgesia’, ‘opioid OR buprenorphine’, or
‘nonsteroidal anti-inflammatory drug (NSAID) OR
NSAID OR meloxicam OR carprofen OR ketoprofen
OR indomethacin OR acetaminophen OR paraceta-
mol’, that number decreased to 818 articles: a difference
of 48,448 articles concerning studies with both tumours
and surgery in mice that listed no analgesics. It may be
that many of these actually used analgesia but did not
disclose it.3 However, such under-reporting is not usu-
ally the case.4 Of those studies that did list analgesics,
most evaluated their effects on tumour-associated pain
or therapeutic effects on tumour growth. For example,
whereas NSAIDS have been found to impede tumour
development in some orthotopic tumour models in
rodents,5–7 some opioids can enhance cancer growth,
often via suppression of the immune system.8,9
However, pain or stress due to surgery, anaesthesia or
even sub-optimal housing can also alter tumourigen-
esis.10–16 Analgesics including buprenorphine and indo-
methacin can minimise surgery-associated changes,
bringing tumour development closer to that observed
in a non-surgical model. The mechanism could involve
aspects such as preventing hypothalamic–pituitary–
adrenal (HPA) axis up-regulation or minimising
immunological impacts, such as maintaining natural
killer cell functioning.8,17
The present investigations aimed to evaluate the
impacts of meloxicam or buprenorphine on tumour
growth in two orthotopic mouse cancer models:
in BALB/c mice inoculated with 4T1 mammary car-
cinoma, and then in C57BL/6NCrl mice with B16
melanoma. The 4T1 work also assessed the effects of
using surgery for tumour implantation, which rather
unusually is optional, and of using single- or multiple-
buprenorphine dosing. It was hypothesised that provi-
sion of pain relief, rather than being confounding,
might both improve welfare and enhance study validity.
Materials and methods
Ethical approval
All work was undertaken according to the Animals
(Scientific Procedures) Act 1986 under Home Office
Licence Authority with approval from the Newcastle
University Animal Welfare Ethical Review Body
(AWERB).
Design
Figure 1 shows the final mouse numbers and treat-
ments. Individuals were assigned using a random
number generator (https://www.random.org).
As concerns about using analgesics in cancer studies
mainly relate to tumour growth alterations, the inten-
tion was to investigate from a ‘severe case’ perspective,
so the analgesic dose rates were purposefully high com-
pared with those usually recommended.18
Welfare was assessed using body weight changes,
peripheral nociceptive sensitivity alterations (using
von Frey and Hargreaves testing) and by recording
behaviour changes post-procedurally and as cancer
developed. All mice were initially pre-treated with a
single dose of meloxicam, buprenorphine or saline
prior to 4T1 or B16 cancer inoculation. The 4T1 mam-
mary carcinoma cell line was tested as cells are inocu-
lated orthotopically; however, this can be achieved
either non-surgically or surgically, via percutaneous
injection, or following surgical exposure of the fat
pad.19 We wished to assess whether, as has previously
been suggested,19 unnatural surgical implantation actu-
ally provides a more reliable model of human breast
cancer, and evaluate the impact of distress or post-
surgical pain on tumour development. Study 1 there-
fore had tumours implanted both in conjunction with
surgery or using anaesthesia only. Mice were inoculated
with 4T1 mammary carcinoma or saline, the latter to
permit assessment of the effects of surgery or anaesthe-
sia in the absence of analgesics or cancer. Having
assessed the effects of a single buprenorphine dose,
study 1 was extended to examine multiple doses.
Accordingly, a second cohort of mice was tested, with
additional buprenorphine or saline being given at 12
and 24 h following tumour inoculation. Initial analyses
found no indication that it would be beneficial to test
multiple doses of meloxicam.
The two cohorts in study 1 are respectively referred
to as the 4T1 single-dose and multiple-dose groups. All
mice in cohort 2 received 4T1 cancer inoculation.
Studies of B16 melanoma do not usually involve sur-
gery. Cells are injected intravenously and primarily seed
the lungs. Therefore, in study 2 all mice were inoculated
intravenously with B16 melanoma following a single
pre-treatment with saline, meloxicam or buprenor-
phine. The aim was to determine whether meloxicam
or buprenorphine altered metastatic tumour spread to
the lungs.
Group sizes were established using data from a pre-
vious study where between 8 and 10 mice per group
achieved 80 to 85% power.20
Animals and husbandry
Mice were supplied by Charles River (Margate, Kent,
UK). They were certified free of the common pathogens
listed on their website (http://www.criver.com/pro-
ducts-services/basic-research/health-reports/europe-
asia/uk-by-species). They weighed 18 0.25 g. For
2 Laboratory Animals 0(0)
study 1 (4T1 mammary carcinoma) 108 female BALB/c
mice were used. Study 2 used 30 female C57BL/6NCrl
mice inoculated with B16 melanoma. These strains were
chosen because they are syngeneic for the tumour cell
line each was to be inoculated with. The 4T1 cells used
in study 1 were derived from spontaneous mammary
tumours in BALB/c mice, whereas the B16 melanoma
cells used in study 2 were from C57BL/6 mice with
spontaneously developing melanoma. They were
acclimatised for one week in groups of 2–3 in individu-
ally ventilated cages (Arrowmight, Hereford, UK) con-
taining hardwood bedding (Aspen, BS and S Ltd,
Edinburgh, UK), a cardboard tube, chew blocks and
sizzle nest (B and K Universal, Hull, UK). Food (R&M
no.3, SDS Ltd, Essex, UK) and tap water was provided
ad libitum. Cages were cleaned once per week. The
holding room was kept at 22 2C and 27–40% humid-
ity on a 0700–1900 light cycle.
Figure 1. Treatments combinations and final numbers. Mice were female BALB/c inoculated with saline or 4T1
mammary carcinoma (Study 1), or female C57BL/6NCrl inoculated with B16 melanoma (Study 2). 4T1 mice underwent
laparotomy or only anaesthesia (Surgery¼ Yes/No). Cohort 1 received one (Dose(f)¼Single) s/c pre-inoculation injection
(Pre-Treat) of saline (1 ml/kg), meloxicam (Melox: 10 mg/kg) or buprenorphine (Bup: 0.2 mg/kg). Cohort 2 received the
same saline or buprenorphine pre-treatment as cohort 1, but treatment was repeated at 12 and 24 h (Dose(f)¼Multiple).
Boxes in the ‘Cancer’ column contain mouse numbers. Black boxes show groups inoculated with cancer and clear boxes
those that were non-cancer controls. Mice in the B16 study (Study 2) did not have surgery (surgery¼N/A). All were
inoculated with B16 melanoma after one s/c pre-treatment of either saline (1 ml/kg), meloxicam (10 mg/kg) or bupre-
norphine (0.2 mg/kg).
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Tumour inoculation and treatments
The tumour cells were obtained from Caliper Life
Sciences (Waltham, MA, USA) and were cultured fol-
lowing vendor recommendations. They were confirmed
pathogen free by the IMPACT Profile I (PCR) at the
University of Missouri Research Animal Diagnostic
and Investigative Laboratory. The cells were lucifer-
ase-expressing 4T1-luc2 mammary carcinoma (4T1)
(developed by Kim et al.21) or B16-F10-luc-G5 melan-
oma (B16) (Xenogen Corporation, Alameda,
California, USA). All inoculations were performed
between 8 and 11 a.m. in batches of 8–10 mice.
In the 4T1 study mice were anesthetised with isoflur-
ane in oxygen (4–5%; 0.5–1 l/min) and maintained at 2–
3% isoflurane in oxygen (0.25–0.5 l/min) via a nose
cone. Body temperature was kept between 36C and
38C using a heat pad (Harvard Apparatus,
Edenbridge, Kent, UK). Absence of pedal withdrawal
responses was used to ensure adequate depth. After eye
ointment was applied (Pliva Pharma Ltd., Zagreb, HR)
the mice were subcutaneously (s/c) injected with saline
(1ml/kg), buprenorphine (0.2mg/kg; ‘Vetergesic’,
Reckitt-Coleman, Hull, UK) or meloxicam (10mg/kg;
Boehringer Ingelheim, Labiana Life Sciences S.A.,
Terrassa, Spain). The fourth mammary gland was
then inoculated percutaneously with 100 ml Dulbecco’s
Phosphate Buffered Saline (DPBS) containing 1 106
4T1-luc2 cells, or the same volume of 0.9% sterile
saline.
Mice in the multiple-dose 4T1 study (cohort 2) were
subcutaneously treated with saline (1ml/kg) or bupre-
norphine (0.2mg/kg) before tumour inoculation, and
then at 12 and 24 h after tumour inoculation. All mice
in the 4T1 study were prepared as if for surgery; the
abdomen was first shaved and sprayed with chlorhexi-
dine (Hydrex derma-spray, Leeds, UK), but only half
subsequently underwent a 1.5 cm midline laparotomy
lasting 15min. This was completed exactly as previ-
ously described,22 but without abrasion of the ileum,
and the skin was closed using a continuous subcuticular
suture (4/0 polydioxanone; Ethicon, Livingston, UK)
rather than mattress sutures. The same veterinary sur-
geon performed all surgeries. The non-surgery mice
underwent 15min of isoflurane anaesthesia only.
In the B16 study mice received a single s/c pre-
treatment with saline (1ml/kg), meloxicam (5mg/kg)
or buprenorphine (0.2mg/kg) just prior to restraint in
a 50ml syringe cartridge modified to expose the tail.
They then received an intravenous (i/v) injection of
100 ml of DPBS containing 5 105 B16-F10-luc-G5
melanoma cells via the tail.
All mice recovered in a warming cabinet set at 35
1C for 30 minutes before being returned to the
animal holding room. Apart from when mice were
imaged, all data were collected in the holding room
by treatment-blinded staff. All staff involved in data
collecting data were cross-trained to ensure consistency.
Nociceptive testing
Mechanical response thresholds were obtained using
‘The Mousemet’ electronic von Frey (eVF) device
(Topcat Metrology, Ely, UK). Animals were placed
into one of four separate raised runs that had
Plexiglas sides and steel rod floors. After a 10min
acclimation period six readings were obtained from
each hind-paw, allowing at least 2min between each.
The probe force rise rate was 1 g/s applied when ani-
mals were stationary. The 4T1 eVF thresholds were
tested at baseline (between 12 and 4 p.m. the day
before inoculation), at 24 h following recovery from
anaesthesia, and then on days 7, 14, 19 and 22.
In the B16 study eVF readings were taken at baseline,
1 h and on days 5, 9, 13 and 17. Equipment malfunc-
tion meant baseline eVF readings were missed in the
first 10 4T1 mice.
Thermal nociceptive testing used a Hargreaves
apparatus (Model 37370; Ugo Basile, Italy). This had
six clear plastiglas enclosures (11 cm 17 cm 14 cm)
to which mice were first acclimated for 5min.
Baseline latencies were obtained between 12 and
4 p.m. the day before tumour inoculation. In the 4T1
study Hargreaves data were subsequently recorded at
24 h, and on post-inoculation days 5, 8, 14, 20 and 22.
The B16 recordings were at baseline, 1 h and on days 5,
9, 13 and 17. Heat intensity was 280mW/cm2 with a
30 s cut-off time. Three readings were obtained from
each hind-paw, allowing 2 minutes between each,
again when mice were stationary.
Behaviour recordings
Mice were filmed individually for 10min in three clear
cages containing only sawdust (Type 1144B,
Techniplast UK Ltd, Northamptonshire, UK).
Recordings were made between 1 and 4 p.m. using
three Canon Legria HFM 506 cameras placed 30 cm
from each cage. The 4T1 recordings were one day
before inoculation (baseline), at 3 and 24 h, and then
on days 5, 8, 14, 20 and 22. The B16 mice were filmed at
baseline, 1 h and on days 5, 9, 13 and 17.
Imaging
D-Luciferin (PerkinElmer, Beaconsfield, UK) was dis-
solved in DPBS to 15mg/ml and frozen at 80C. Mice
were anaesthetised with isoflurane in batches of three
and imaged in an IVIS Spectrum 200 (PerkinElmer,
Beaconsfield, UK) on a stage maintained at 36C.
Anaesthesia was provided by face-mask delivery
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of 1.5–2% isoflurane in 0.5 l/min oxygen. Once thawed
to room temperature, 150mg/kg luciferin was injected
s/c. Peak reactivity occurred 12min later, so after this
open filter scans were taken at 7, 12, 15, 19 and 22 days
in the 4T1 study. The B16 mice were imaged at 24 h and
on days 5, 9, 13, 17 and 19.
End-point criteria/terminal assessment
Mice were weighed daily and examined according to
United Kingdom Coordinating Committee for Cancer
Research (UKCCCR) guidelines.23 The end-point was
reached if there was >20% body weight loss alongside
poor coat condition and mobility. If these signs were
present, after a final IVIS scan mice were to be eutha-
nased by cervical dislocation without recovery from
anaesthesia. Any remaining B16 or 4T1 mice were to
be euthanased on days 19 or 22 respectively. All mice
underwent a necropsy with ex-vivo imaging of primary
tumours, kidney, liver, intestines and lungs. The 4T1
primary tumours were removed and measured with cali-
pers (Mitutoyo, UK Ltd). In the 4T1 study 12 mice had
to be excluded due to tumour inoculation error, which
resulted in the rapid development of carcinomatosis.
There were no correlations between these occurrences
and treatment or surgery. Three B16 mice were also
excluded, two due to injection error, and one that devel-
oped a very large ovarian metastasis. Apart from these
no other mice were euthanased early and the exclusions
left sufficient final numbers (shown in Figure 1).
Data analysis
All statistical analyses were performed using the
Statistics Package for the Social Sciences (SPSS soft-
ware version 22.0, SPSS Inc., Chicago, USA). The
two cohorts in the 4T1 study had to be analysed sep-
arately. Repeated measures ANOVA with probability
corrected multiple comparisons (Bonferroni) was used.
In the 4T1 study the between-subjects factors were
‘drug’, ‘surgery’ and ‘cancer’ status, and ‘time’ was
the within-subjects factor. The B16 analysis included
the factors ‘drug’ and ‘time’ only. The baseline eVF
thresholds were highly uniform, so to balance the
analysis the missing 4T1 values were replaced with the
corresponding group mean. The 4T1 eVF data showed
no baseline left or right paw bias so values were aver-
aged at each time-point. The 4T1 Hargreaves data
showed a clear paw bias so these data were analysed
separately. Automated behaviour analysis software
(HomeCageScan (HCS): Version 3; Clever Systems
Inc., USA) was used to obtain the frequency of rearing
and walking (‘Rear-up’, ‘Come Down’, ‘Remain Rear-
up’ and ‘Walk Left’, ‘Right’ or ‘Slow’) from the video
material at each time-point. The 4T1 behaviour data
required Log10 transformation before undergoing
ANOVA. Figure 3(a) therefore shows back-trans-
formed means with 95% confidence intervals
(95%CI). In the B16 study the raw behaviour data
were acceptable. Living Image software (PerkinElmer,
Beaconsfield, UK) quantified tumour burden as the
Total Flux (TF; photons/sec/mW/cm2) of biolumines-
cent signals within auto-generated (2% threshold)
regions of interest (ROIs) over the mammary or lung
regions, with additional ROIs over the abdomen to
detect any other metastases. TF on the last day
provided a measure of 4T1 final burden; however, as
signals emerged by day seven it was also possible to
estimate the average growth rate as the change in TF
from day seven to the final scan on day 22 ((TF on day
22 – TF on day 7)/15). No signals were apparent in the
B16 study until day 17, which was two days before the
final scan, so only the final TF values were assessed.
The 4T1 ex-vivo primary tumour burden (volume) was
calculated from the caliper measurements (4/3*II*r3).
Bivariate correlation analysis (Pearson’s R) was used
to determine how well the imaging data predicted true
tumour burden. Apart from the 4T1 growth data
(Figure 4(a)) all imaging data, including in the B16
study were Log10 transformed before applying
ANOVA. Figures 4(b) and 4(c) therefore show back-
transformed means þ95%CI. All other results are
mean values 1SEM. The B16 weight data underwent
ANOVA as total change from baseline. The 4T1 body-
weight data were non-homogeneous so percentage
weight changes were used. Original data are available
from an online repository (http://figshare.com).
Results
4T1 study
Body weight: Surgery and multiple doses of bupre-
norphine was associated with loss in body
weight. Six mice were excluded, having lost between
11 and 24% of baseline weight by day one (>3 times
the group average). They were all in the cohort 1, one
from each drug-treated non-surgery cancer group, two
from the saline non-cancer surgery group and two
cancer-treated mice that received meloxicam before sur-
gery. This reduced group sizes to six or seven, which
was considered acceptable. Over the first three days the
single-dose surgery groups lost weight whereas the non-
surgery mice gained, but only 2 versus þ2% (f(1,
52)¼ 9.1, p¼ 0.004). Neither cancer inoculation nor a
single dose of meloxicam or buprenorphine resulted in
significant weight change. Mice in the multiple-dose
cohort lost only negligible weight following surgery.
Multiple-dose buprenorphine was associated with
2% greater weight loss over the first three days
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(f(1, 31)¼ 5.5, p¼ 0.02). This was more obvious in the
non-surgery group, but was not significant. By day six
all mice exceeded baseline weight and showed contin-
ued gains until day 19, with no lasting effects of surgery
or pre-treatment. Although cancer-bearing mice in each
cohort lost weight as the study ended, this was not sig-
nificantly more than non-cancer controls.
Nociceptive testing: Multiple doses of buprenorphine
significantly increased mechanical thresholds,
whereas cancer growth significantly decreased
them. All groups showed comparable baseline eVF
thresholds. Mice given buprenorphine repeatedly in con-
junction with surgery (all of which were cancer inocu-
lated) were the only group that showed significantly
increased eVF thresholds (greater force to respond) (f(3,
28)¼ 7.5, p¼ 0.001), that is, decreased nociception, but
only at the 24h time-point. As the other mice responded
similarly in the days following treatment the responses
were pooled within the single- or multiple-dose cancer-
bearing groups (ignoring surgery) and the two saline,
non-cancer control groups. Figures 2(a) (eVF) and 2(b)
(Hargreaves) show the results. The eVF thresholds
declined more over time in cancer-bearing mice in
both the single- and multiple-dose cohorts (‘Time’
(f(5, 49)¼ 8.4, p< 0.001; f(5, 26)¼ 21.5, p< 0.001,
respectively), but most obviously spanning days 19–22
in mice in the single-dose cohort (Figure 2(a); ‘Time’ 
‘Cancer’ interaction (f(5, 49)¼ 3.5, p¼ 0.008)), indicating
increased nociception as the tumours grew.
Cancer growth reduced the latency to withdraw from
a noxious heat source. Hargreaves latencies were also
unaffected by surgery or pre-treatment. Responses from
Figure 2. Nociceptive testing results. (a) Mean (combined paws) electronic von Frey (eVF) thresholds (grams 1SEM) in
BALB/c mice in the single- and multiple-dose 4T1 cohorts versus non-cancer controls; showing the significant decline
over time in all mice, but more so in cancer groups. (b) Left paw thermal withdrawal thresholds (meanSEM) in the same
groups as (a); showing increased thermal sensitivity as tumours grew. (c) eVF threholds (both paws) in the B16 groups
where thresholds generally declined during tumour development. (d) Mean thermal (both paws) withdrawal thresholds
(SEM) in the B16 groups showing thermal response thresholds were not significantly altered as cancer developed.
Significant (Sig.) ‘factors’ from repeated measures ANOVA and p-values are indicated.
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each paw generally occurred sooner over time, but the
left paw responded sooner than the right. As a result,
Figure 2(b) shows data from this paw only with groups
combined as in Figure 2(a). Mice in the single-dose
cohort showed a modest latency decrease from baseline
to 24 h (f(1, 53)¼ 5.5, p¼ 0.023), indicating decreased
nociception. After this cancer development was asso-
ciated with a further reduction in response latency
(‘Time’  ‘Cancer’ interaction; f(6, 318)¼ 5.6,
p< 0.001), that is, tumour growth was associated with
increased nociception. In the multiple-dose cohort both
the left and right paws were sensitised by 24 h (right:
f(1, 31)¼ 7.3, p¼ 0.001; left: f(1.31)¼ 18.2, p¼ 0.0001),
and both paws then responded sooner as tumours grew
(right: f(6,186)¼ 2.1, p¼ 0.049; left: f(6, 186)¼ 5.3,
p< 0.0001), but as the significance values indicated,
the left paw became the most sensitised.
Behaviour: While surgery and analgesic treatments
did not significantly alter behaviour, spontaneous
active behaviours decreased as tumours
grew. Rearing and walking were unaffected by drug
administration or surgery at any point during either
the single- and multiple-dose 4T1 studies. As a result,
these behaviours were combined to create a summary
variable ‘Behave’ which was used to assess any later
effects of cancer development in each cohort of
mice.22,24 Figure 3(a) shows the activity changes in
the control groups (saline, non-cancer) versus the
cancer-bearing mice in the single- and multiple-dose
cohorts. At 3 h all mice were more active than at base-
line (f(1, 61)¼ 15.8, p¼ 0.001; f(1, 34)¼ 9.1, p¼ 0.005,
cohorts 1 and 2, respectively). This dissipated over 24 h
and activity was relatively normal until between days 20
and 22, where compared with non-cancer controls,
tumour-bearing mice in cohort 1 showed a greater
activity decline (‘Time’ ‘Cancer’ interaction;
f(1, 61)¼ 7.0, p¼ 0.011). However, this was not appar-
ent in the equivalent cancer-bearing mice in cohort 2.
Tumour growth as indicated by IVIS signal intensity:
Surgery was a more significant tumour growth mod-
ulator than analgesia. Signal intensity increased more
rapidly in mice in cohort 1 that underwent surgery
compared with non-surgery controls (20.8 159
vs. 162 24 109 photons/s/day; f(1, 38)¼ 24.8,
p< 0.0001, Figure 4(a)), and they also showed stronger
signals on the last day (f(1, 38)¼ 25.8, p< 0.001). In
cohort 2 the surgery/non-surgery growth difference
was somewhat less, but still significantly greater in the
mice that underwent surgery (27.59 33 vs. 123
26 109 photons/s/day; f(1, 31)¼ 5.1, p¼ 0.03). The
ex-vivo caliper measurements indicated larger volume
tumours in mice that underwent surgery (554 50 vs.
420 40mm3; all cancer-bearing groups combined).
The lung scanning results reiterated the impact of
surgery, where in both cohorts the surgery groups
showed more extensive lung seeding (single:
f(1, 44)¼ 12.1, p¼ 0.001; multiple: f(1, 35)¼ 9,
p¼ 0.005, Figure 4(b)). The greatest spread was in the
groups pre-treated with saline before surgery either as a
single dose (Sal/S; f(1,16)¼ 9.7, p< 0.001) or given
repeatedly (Sal/M; f(1,19)¼ 22.4, p< 0.001). Notably,
metastatic signals in the meloxicam or buprenorphine
groups in cohort 1 (Mel/S, Bup/S) were similar to those
in the non-surgery groups (p¼ 0.258, p¼ 0.23, respect-
ively), and in cohort 2 the surgery/non-surgery groups
given buprenorphine repeatedly were almost identical
(Bup/M; p¼ 0.83). The ex-vivo measurements showed
mice in cohort 1 with the largest tumours had more
metastases (Pearson’s r¼ 0.34, p¼ 0.024) and more
rapid tumour growth over days 7–22 (R2¼ 0.4,
p< 0.001).
B16 study
Body weight: Mice treated with buprenorphine lost
slightly more weight than those receiving saline or
meloxicam. The three test groups had similar initial
weights (22.8–23.6 g) and there were no significant
losses on day one. By day three mice receiving bupre-
norphine lost more weight than those given saline or
meloxicam (f(1,27)¼ 3.8, p¼ 0.036), but an average of
only 1 g more. After this the saline and meloxicam
groups maintained weight and the buprenorphine
group gained, but only slightly more (1 g).
Nevertheless, there was a significant ‘Time’ effect and
a ‘Time’ ‘Pre-treatment’ interaction (f(17, 408)¼ 5.8,
p< 0.001; f(17, 408)¼ 2.7, p< 0.001, respectively).
There were no significant weight changes as the study
ended.
Nociceptive testing: Mechanical thresholds, but not
latency to withdraw from thermal stimulus, signifi-
cantly decreased as cancer developed. Baseline eVF
thresholds were similar across the three groups and both
paws responded similarly (2.7 0.6 g; Figure 2(c)). Pre-
treatment had no effect on post-inoculation thresholds
which continued to decline as cancer developed (‘Time’
significant; f(5, 120)¼ 30, p< 0.0001). Although there
was a partial stabilisation between days five and nine,
thresholds were lower than at baseline at every subse-
quent time-point (p 0.001). The baseline B16
Hargreaves latencies were also similar initially, and
although they also declined from baseline to 1 h (from
3.9 0.7 to 3.5 1.1 s; Figure 2(d)), not significantly
(p¼ 0.06).
Behaviour: Buprenorphine significantly increased
walking behaviour. Figures 3(b) and 3(c) illustrate
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rearing and walking frequency separately because they
were affected by buprenorphine differently. Overall,
both were significantly increased at 1 h following
tumour inoculation (rearing: f(1, 26)¼ 151, p< 0.001;
walking: f(1, 26)¼ 58, p< 0.001); however, relative to
the behaviour of mice in the meloxicam or saline
groups, at the 1 h time-point pre-treatment with
buprenorphine was associated with increased walking
(Figure 3(b); f(2, 26)¼ 24.6, p< 0.001) and less rearing
(Figure 3(c); f(2, 26)¼ 13.5, p< 0.001). Both rearing
and walking became normal by day five and remained
as such until the study ended.
Tumour growth, as indicated by IVIS signal intensity:
Meloxicam, but not buprenorphine, reduced lung
metastases. There was no significant change in TF
until day 17, but after this development occurred
rapidly. There was no difference in final day signal
intensity between mice that had received saline or
buprenorphine, but as Figure 4(c) shows, signal inten-
sity was lower in mice that received meloxicam
(p¼ 0.014, p¼ 0.01; meloxicam vs. saline or buprenor-
phine, respectively). Neither drug affected abdominal
metastases.
Discussion
Out of concern that analgesics can alter tumour devel-
opment, animal cancer studies often withhold them.
However, this ignores the possibility that cancer-related
pain or distress could cause unnecessary scientific vari-
ation. Two studies were undertaken to assess whether
Figure 3. Behaviour results. (a) The geometric mean frequency (1SEM) of the summary measure ‘Behave’ (þ95%
Confidence Intervals (CI)) in mice in the 4T1 single- or multiple-dose cohorts versus non-cancer single-dose controls,
illustrating the post-procedural activity enhancement but relatively normal behaviour, even when cancer was well
developed. The mean frequency (SEM) of walking (b) or rearing (c) in the B16 groups; illustrating that at 1 h mice walked
more following s/c saline (1 ml/kg) or meloxicam (10 mg/kg), but especially more after buprenorphine (0.2 mg/kg) com-
pared with baseline (**: p< 0.001(b)). All mice also reared more at 1 h (**: p< 0.001(c)) except those that received
buprenorphine. The effects of buprenorphine and those in the meloxicam and saline groups subsided by five days and
behaviour was subsequently normal.
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buprenorphine or meloxicam altered tumour growth in
BALB/c mice developing 4T1 mammary carcinoma,
and in C57BL/6NCrl mice inoculated with B16 melan-
oma. Both studies used luciferase-expressing cells lines
so tumour growth and spread could be determined
using bioluminescent imaging. The 4T1 study included
groups undergoing tumour inoculation in conjunction
with surgery. A secondary aim was to assess any pain
the inoculation procedures might cause, and whether
pain occurred as tumours grew. This was assessed
using body weight and behaviour changes, and by
recording parallel signs of nociceptive responding via
thermal and mechanical nociceptive threshold testing.
It was hypothesised that mice undergoing surgery
would show behaviour changes and nociceptive sensi-
tivity changes suggesting underlying pain, but that
these effects would be minimised in the groups pre-trea-
ted with meloxicam or buprenorphine. Neither the B16
or 4T1 inoculation procedures appeared to cause sig-
nificant pain, and there was also little evidence of
pain as each type of cancer developed. It was predicted
that the B16 inoculation and 4T1 percutaneous inocu-
lation procedure would be relatively harmless, but
the relatively benign effect of undertaking 4T1 inocula-
tion paired with surgery was unexpected. The main
findings were that surgery significantly increased 4T1
tumour growth and metastatic spread, but provision
of pre- and post-operative buprenorphine neutralised
Figure 4. Imaging results. (a) Mean rate of development of signals from 4T1 primary tumours over days 7–22 (TF 109
photons/s/cm2/day SEM) in mice that underwent surgery or not, illustrating the significant greater surgery-related
tumour growth rate in both 4T1 cohorts (**: p< 0.001: *: p< 0.05). (b) Geometric mean TF (photons/s/cm295% CI) of ex-
vivo metastatic lung signals in mice in the single (S) or multiple (M) dose 4T1 cohorts pre-treated with saline (Sal; 1 ml/kg),
meloxicam (Mel; 10 mg/kg) or buprenorphine (Bup; 0.2 mg/kg) before undergoing surgery or not. In the multiple- and
single-dose saline groups (Sal/S or Sal/M) surgery significantly increased lung metastases (**: p< 0.001), but bupre-
norphine given singly and especially repeatedly (Bup/S, Bup/M) protected against greater tumour spread (buprenorphine-
treated surgery vs. non-surgery groups, p¼NS). (c) The geometric mean TF (photons/s/cm295% CI) on the last day in
the B16 study, illustrating meloxicam pre-treatment significantly reduced lung seeding compared with saline or bupre-
norphine (*: p< 0.05).
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the impact of surgery on the tumour model. Providing
peri-procedural analgesia was therefore shown to be
beneficial, by more closely approximating tumour
growth to the spontaneous development experienced
by human patients that this research is designed to
model.
The BALB/c mice in the 4T1 study were predicted to
show an impact of surgery comparable with that in
another of our recent investigations in which BALB/c
mice underwent laparotomy but showed substantially
reduced behavioural activity and significant post-
surgical weight losses.22 However, on this occasion
they generally became more active following either
anaesthesia or surgery and maintained body weight.
Albeit the previous BALB/c mice were male, the litera-
ture on sex-related pain sensitivity is highly non-
consensual. The most recent knowledge also suggests
females should be more, rather than less, prone to
pain,25 so although it cannot be discounted, sex was
thought unlikely to account for such opposing post-
surgical outcomes. More relevantly perhaps, the aim
of the previous study was to validate use of an agent
that was supposed to enable imaging of inflammation.
The laparotomy procedure was therefore modified such
that after the agent was injected it included 60 s of vis-
ceral abrasion. These additional manipulations may
have previously been aggravating to normal behaviour,
and it was possibly also relevant that the two studies
had different surgeons. Whereas the previous study
used mattress sutures, in this study a continuous sub-
cuticular suture was used to close the skin. This may
have been a refinement that helped to limit alterations
in behaviour, but it is impossible to verify whether these
protocol variations contributed to the lesser impact of
surgery found here. An obvious limitation of this study
is that we did not have the opportunity to replicate the
study to determine if the pain responses measured were
reproducible.
The other noticeable effect of surgery was that
both thermal and mechanical sensitivity had increased
at 24 h. However, this change was also apparent in
4T1 non-surgery controls, indicating pain alone
may not have been the source of this sensitivity.
Alterations as a result of drug treatment were
evidenced by the increase in 4T1 mechanical thresholds
at 24 h following multiple-dose buprenorphine; how-
ever, this was only seen following surgery and not, as
would have been predicted, in the equivalent non-sur-
gery group. Finally, stress causes analgesia; but it is
severe or prolonged the opposite can occur, that is,
hyperalgesia.26–28 However, while the stress of the sur-
gery may have been sufficient to cause hyperalgesia, the
relatively minor procedure used in the B16 investigation
was unlikely to be sufficient to induce this level of
stress.
The only obvious behavioural change in either study
was in the buprenorphine-treated B16 mice, which
showed a substantial initial increase in walking and
lack of rearing. These were most probably non-specific
effects as previously seen in buprenorphine-treated mice
following either vasectomy or laparotomy.24,29 In gen-
eral, the activity increases following B16 inoculation
may have reflected the normal tendency of mice to
explore a novel environment, in this case the filming
cage. Although hyper-locomotion can be caused by
chronic stress,30,31 it is again doubtful this could have
been the case following the short period of restraint
needed for B16 inoculation.
Nociceptive responding continued to increase as
4T1 tumours grew (Figure 2(a) and 2(b)), and in the
B16 study there was a less obvious but still significant
reduction in mechanical thresholds as the study ended
(Figure 2(c)). The nociceptive threshold was reduced,
indicating that the mice experienced greater pain.
However, by the time these changes were most obvi-
ous, the mice in both studies had been exposed to
numerous different potential stressors. Apart from
being isolated from cage-mates during nociceptive test-
ing and filming, they underwent repetitive anaesthesia
for imaging, daily weighing and a health inspection,
and in the 4T1 study also restraint for tumour palpa-
tion. It is possible that the combined impact of these
experiences was sufficient to cause some degree of
hyperalgesia. In a previous study, mice with bladder
cancer20 demonstrated evidence of pain by showing an
enhanced conditioned place preference for morphine
as their tumours grew. Here, the B16 mice behaved
relatively normally; their mechanical response thresh-
olds showed only a modest decrease as cancer devel-
oped, and there were no significant thermal response
alterations. As the 4T1 study ended, increased noci-
ceptive sensitivity was accompanied by a minor reduc-
tion in behavioural activity confined to mice in cohort
1 and not those bearing the same cancer in cohort 2
(Figure 3(a)).
Imaging was used to determine any drug-related
tumour growth changes. Although meloxicam reduced
B16 lung seeding as compared with saline or buprenor-
phine, buprenorphine had no effect on this model of
metastatic growth (Figure 4(c)), and neither analgesic
had any detrimental impact on 4T1 tumour growth
consistency or metastases. However, surgery caused
4T1 tumours to develop more rapidly and spread
more (Figure 4(a) and 4(b)). Such changes have previ-
ously been attributed to removal of anti-angiogenesis
control, growth factor release, or metabolic, neuroen-
docrine and immunological suppression.6,11,13 Several
previous studies have also shown stress due to anaes-
thesia, pain or hypothermia12,32–34 can promote many
types of cancer.10–16 Although it is unknown which
10 Laboratory Animals 0(0)
aspect contributed most to the present 4T1 acceler-
ation, because it was partially neutralised by buprenor-
phine, stress again seems the most likely candidate.
While surgery alone led to an increase in lung metas-
tases (Figure 4(b)), this was prevented if mice had
repeated peri-operative doses of buprenorphine at a
dose commonly used for pain prevention.35 Previous
studies have found analgesics can reduce surgery-asso-
ciated increases in tumour recurrence,12,13 and there are
also examples where buprenorphine had either no
impact or supported normal tumour growth.8,9
Perhaps due to these aspects and its post-surgical
stress-preventative properties,9 giving buprenorphine
was beneficial to model consistency. Although this
obviously needs confirmation with other cancer
models, it suggests that in some cases, especially in
cancer studies requiring surgery, that mice might bene-
fit from receiving some form of pain or stress preven-
tion. Therefore, future research goals include similar
evaluations as performed in these studies in additional
orthotopic tumour models requiring surgery.
Furthermore, a meta-analysis of the relative success
of anti-neoplastic therapies developed in mouse
tumour models requiring and not requiring surgery,
as well as in studies providing or not providing peri-
operative analgesia, would allow further exploration of
the translation of the results of murine orthotopic
tumour models to human health.
Mammary tumours most commonly occur in
females and therefore we chose to assess the 4T1
tumours in female mice. However, it might be asked
why the B16 mice were also female. Although this
has been dealt with before,20 it was to answer the
need for studies that do not only consider males. A
minor point to mention was the good agreement
between the caliper measurements and the imaging
data. Although manual tumour burden estimates are
generally inaccurate, in this case they partially pre-
dicted eventual 4T1 tumour spread.
These studies document minimal impacts of anal-
gesia on tumour growth in at least one cancer model.
Minimising surgical stress via any means possible seems
a logical refinement that could remove some current
barriers to precautionary analgesic use in animal
cancer studies. While possibly less critical in basic sci-
ence research, pre-clinical studies intended to directly
model benefits for human patients may arguably be
best served by treating animals similarly to human
cancer patients, where analgesic use is normal and usu-
ally beneficial.
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Re´sume´
Les mode`les orthotopiques murins de cancer exigent souvent une chirurgie, laquelle peut potentiellement
causer douleur et de´tresse, mais les analge´siques sont souvent exclus car ils peuvent alte´rer le de´veloppe-
ment des tumeurs. Deux cancers orthotopiques implante´s ont e´te´ e´tudie´s chez des souris pre´alablement
traite´es par me´loxicam (10 mg/kg), bupre´norphine (0.2 mg/kg) ou une solution saline (1 ml/kg). Les tumeurs
ont e´te´ image´es et le bien-eˆtre social a e´te´ e´value´ en mesurant le poids du corps, le comportement et les
re´ponses nociceptives. Dans l’e´tude 1, les souris BALB/c ont e´te´ inocule´es avec un carcinome mammaire 4T1
ou une solution saline pendant la chirurgie ou l’anesthe´sie. Le pre´traitement avec une dose unique de
bupre´norphine s’e´tant re´ve´le´ be´ne´fique pour la constance de la croissance du cancer, une deuxie`me cohorte
de souris a rec¸u en plus une solution saline ou de la bupre´norphine a` 12 et 24 heures. L’ope´ration a entraıˆne´
une augmentation de la croissance des tumeurs mammaires et des me´tastases pulmonaires. Ces effets
12 Laboratory Animals 0(0)
inde´sirables ont e´te´ atte´nue´s par la bupre´norphine utilise´e en pre´traitement, surtout lorsqu’elle e´tait admin-
istre´e de fac¸on re´pe´te´e. Les souris porteuses de tumeurs mammaires sont devenues moins actives et les
seuils nociceptifs ont diminue´ au fil du temps, indiquant la pre´sence d’un certain malaise au fur et a` mesure
que les tumeurs augmentaient. Dans l’e´tude 2, des souris C57BL/6 ont e´te´ inocule´es par un me´lanome B16.
Ce mode`le non-chirurgical a e´te´ utilise´ pour de´terminer si l’ibuprofe`ne ou la bupre´norphine affectaient
l’ensemencement des poumons par le cancer. Bien que le me´loxicam ait re´duit l’ensemencement des pou-
mons par le me´lanome B16, la bupre´norphine n’a pas eu cet effet. Les seuils me´caniques ont diminue´ au fur
et a` mesure que le cancer s’est de´veloppe´ chez les souris porteuses du me´lanome, mais l’ampleur de cette
diminution s’est ave´re´e insuffisante pour conclure a` l’existence de pre´occupations en matie`re de bien-eˆtre.
Cette e´tude souligne la valeur scientifique de l’utilisation de mode`les non-chirurgicaux, dans la mesure du
possible. Lorsque la chirurgie doit eˆtre effectue´e au moment de l’inoculation de la tumeur, ses effets dev-
raient eˆtre controˆle´s par des analge´siques afin d’accroıˆtre la valeur et peut-eˆtre la translation de la
recherche.
Abstract
Orthotopische Maus-Krebs-Modelle bedu¨rfen oft chirurgischer Eingriffe und verursachen potenziell Schmerz
oder Leid. Analgetika werden jedoch ha¨ufig nicht verabreicht, da sie u. U. die Tumorentwicklung vera¨ndern
ko¨nnen. Zwei orthotopisch implantierte Karzinome wurden bei Ma¨usen untersucht, die zuvor mit Meloxicam
(10 mg/kg), Buprenorphin (0.2 mg/kg) oder Salzlo¨sung (1 ml/kg) behandelt worden waren. Tumore wurden
bildlich dargestellt und das Wohlbefinden wurde anhand von Ko¨rpergewicht, Verhalten und nozizeptiven
Reaktionen bewertet. In Studie 1 wurden BALB/c Ma¨use wa¨hrend der Operation oder Ana¨sthesie mit 4T1
Mammakarzinom oder Salzlo¨sung inokuliert. Da die Vorbehandlung mit einer Einzeldosis Buprenorphin
einem gleichbleibenden Krebswachstum fo¨rderlich schien, erhielt eine zweite Ma¨usekohorte zusa¨tzlich
Salzlo¨sung oder Buprenorphin nach 12 und 24 Stunden. Die Operation resultierte in erho¨htem
Mammatumorwachstum und Lungenmetastasen. Diese unerwu¨nschten Folgen wurden durch
Vorbehandlung mit Buprenorphin verringert, insbesondere bei wiederholter Verabreichung. Mammatumor
tragende Ma¨use wurden inaktiver und nozizeptive Schwellen sanken mit der Zeit als Anzeichen fu¨r gewisses
Unbehagen angesichts zunehmenden Tumorwachstums. In Studie 2 erhielten C57BL/6-Ma¨use B16-Melanom.
Dieses nicht-chirurgische Modell wurde verwendet, um zu ermitteln, ob Meloxicam oder Buprenorphin die
Krebsbesiedlung der Lunge beeinflussten. Meloxicam reduzierte die B16-Lungenbesiedlung, Buprenorphin
jedoch nicht. Mechanische Schwellen sanken mit zunehmender Karzinomentwicklung bei Melanom tragen-
den Ma¨usen, jedoch in einem Ausmaß, das unzureichend war, um schlussfolgern zu ko¨nnen, dass signifikante
Beeintra¨chtigungen des Wohlbefindens zu befu¨rchten sind. Diese Studie unterstreicht den wissenschaftlichen
Wert des Einsatzes nicht-chirurgischer Modelle, soweit mo¨glich. Wenn zur Tumorinokulation eine Operation
erfolgen muss, sollten die Auswirkungen mit entsprechenden Analgetika kontrolliert werden, um den Wert
und mo¨glicherweise die U¨berleitung der Forschungsergebnisse zu optimieren.
Resumen
Los modelos murinos con ca´ncer ortoto´pico a menudo requieren cirugı´a, lo que suele provocar dolor o
malestar. No obstante, los analge´sicos a menudo son negados ya que pueden alternar el desarrollo del
tumor. Se investigaron dos ca´nceres implantados ortoto´picamente en ratones que habı´an recibido meloxicam
(10 mg/kg), buprenorfirna (0.2 mg/kg) o salina (1 ml/kg). Los tumores fueron escaneados y se analizo´ el
bienestar utilizando el peso corporal, el comportamiento y las respuestas nociceptivas. En el estudio 1, los
ratones BAB/c fueron incoculados con carcinoma de mamas 4T1 o salina durante cirugı´a o anestesia. Ya que
un tratamiento previo con una u´nica dosis de buprenorfina parecio´ ser beneficioso para la consistencia de
crecimiento del ca´ncer, un segundo cohorte de ratones tambie´n recibio´ salina o buprenorfina a las 12 y 24
horas. La cirugı´a provoco´ un crecimiento del tumor de mama y una meta´stasis pulmonar. Estos efectos no
deseados fueron aliviados con un tratamiento previo con buprenorfina, especialmente al administrarse repe-
tidamente. Los ratones con tumor de mama fueron menos activos y los lı´mites nociceptivos decrecieron con
el tiempo, lo cual indicaba un malestar a medida que los tumores crecı´an. En el estudio 2, los ratones C57BL/
6 recibieron melanoma B16. Este modelo no quiru´rgico fue utilizado para determinar si el meloxicam o la
buprenorfina afectaban la germinacio´n del ca´ncer en los pulmones. Mientras que el meloxicam redujo la
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germinacio´n pulmonar B16, la buprenorfina no lo hizo. Los lı´mites meca´nicos decrecieron a medida que el
ca´ncer se desarrollaba en los ratones con melanomas, pero la magnitud de esto fue insuficiente para concluir
que habı´a una preocupacio´n significativa por el bienestar de los animales. Este estudio destaca el valor
cientı´fico que tiene utilizar modelos no quiru´rgicos, siempre que sea posible. Cuando se debe realizar inter-
venciones quiru´rgicas en el momento de la inoculacio´n del tumor, los efectos deberı´an controlarse con
analge´sicos adecuados para aumentar el valor y la posible implementacio´n del estudio.
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